Skip to main content
xMedica

NCT05334069ClinicalTrials.gov

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Blinded Reference Set for Multicancer Early Detection Blood Tests

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory…

Observational2,900 participants sought751 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2022-04-19; recorded start 2022-08-18
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 60 conditions.
  • Lead sponsor type recorded as: other.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 745 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 2,900 participants (target), run at 751 sites.

How this score is built
  • Enrolment33/40

    2,000 participants (target)

  • Site count25/25

    745 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 55 months

  • Sponsor scale7/10

    Alliance for Clinical Trials in Oncology has led 96 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

PRIMARY OBJECTIVE: I. To provide a blinded reference set of cancer versus (vs.) non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection. SECONDARY OBJECTIVES: I. Evaluate test performance at the time of initial cancer diagnosis by tumor type. II. Evaluate test performance at the time of initial cancer diagnosis by clinical stage. OUTLINE: Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration. After completion of study, participants are followed up at 1 year.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Ann Arbor Stage I Lymphoma
  • Ann Arbor Stage II Lymphoma
  • Ann Arbor Stage III Lymphoma
  • Ann Arbor Stage IV Lymphoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Gastroesophageal Junction Adenocarcinoma
  • Head and Neck Carcinoma
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Invasive Breast Carcinoma
  • Kidney Carcinoma
  • Malignant Hepatobiliary Neoplasm
  • Malignant Solid Neoplasm
  • Melanoma
  • Muscle-Invasive Bladder Carcinoma
  • Stage I Bladder Cancer AJCC v6 and v7
  • Stage I Breast Cancer AJCC v7
  • Stage I Colorectal Cancer AJCC v6 and v7
  • Stage I Esophageal Cancer AJCC V7
  • Stage I Gastric Cancer AJCC V7
  • Stage I Lung Cancer AJCC v7
  • Stage I Ovarian Cancer AJCC v6 and v7
  • Stage I Pancreatic Cancer AJCC v6 and v7
  • Stage I Prostate Cancer AJCC v7
  • Stage I Uterine Corpus Cancer AJCC v7
  • Stage II Bladder Cancer AJCC v6 and v7
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage II Colorectal Cancer AJCC v7
  • Stage II Esophageal Cancer AJCC v7
  • Stage II Gastric Cancer AJCC v7
  • Stage II Lung Cancer AJCC v7
  • Stage II Ovarian Cancer AJCC v6 and v7
  • Stage II Pancreatic Cancer AJCC v6 and v7
  • Stage II Prostate Cancer AJCC v7
  • Stage II Uterine Corpus Cancer AJCC v7
  • Stage III Bladder Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Stage III Colorectal Cancer AJCC v7
  • Stage III Esophageal Cancer AJCC v7
  • Stage III Gastric Cancer AJCC v7
  • Stage III Lung Cancer AJCC v7
  • Stage III Ovarian Cancer AJCC v6 and v7
  • Stage III Pancreatic Cancer AJCC v6 and v7
  • Stage III Prostate Cancer AJCC v7
  • Stage III Uterine Corpus Cancer AJCC v7
  • Stage IV Bladder Cancer AJCC v7
  • Stage IV Breast Cancer AJCC v6 and v7
  • Stage IV Colorectal Cancer AJCC v7
  • Stage IV Esophageal Cancer AJCC v7
  • Stage IV Gastric Cancer AJCC v7
  • Stage IV Lung Cancer AJCC v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
  • Stage IV Pancreatic Cancer AJCC v6 and v7
  • Stage IV Prostate Cancer AJCC v7
  • Stage IV Uterine Corpus Cancer AJCC v7
  • RISS Stage I Multiple Myeloma
  • RISS Stage II Multiple Myeloma
  • RISS Stage III Multiple Myeloma

Eligibility

Eligibility
SexAll
Ages40 Years – 75 Years
Healthy volunteersYes
Sampling methodNON_PROBABILITY_SAMPLE

Study population

Patients with a cancer diagnosis and participants without cancer and without suspicion of cancer and with a high suspicion of cancer

Eligibility as written in the registry

Inclusion Criteria: * Participants with a cancer diagnosis: Documentation of disease: * Histologic documentation: Histologically confirmed diagnosis of invasive cancer * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma \*\* For leukemia: Type (chronic lymphocytic leukemia \[CLL\], chronic myeloid leukemia \[CML\], acute lymphoblastic lymphoma \[ALL\], acute myeloid leukemia \[AML\]) * For lymphoma (any type): Stage I-IV based on Ann Arbor staging * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS) * One of the following tumor types (synchronous cancers are not allowed and all neuroendocrine tumors are excluded): * Colorectal * Bladder * Head and neck * Hepatobiliary \*\*\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment * Lung * Lymphoma * Leukemia * Ovary \*\*\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment * Pancreas \*\*\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment * Multiple myeloma * Gastric, esophageal or gastroesophageal * Breast * Thyroid * Kidney \*\*\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment * Endometrium \*\*\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment * Prostate * Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention (including surgical excision) * Participants with a cancer diagnosis: Age \>= 40 and =\< 75 * Participants with a cancer diagnosis: No known current pregnancy by self-report * Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy other than the current cancer diagnosis. Non-melanoma skin cancers (such as basal or squamous cell) are allowed. * Participants with a cancer diagnosis: Willingness to provide blood samples for research use * Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL * Participants with a cancer diagnosis: No history of organ transplantation * Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish \* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages * Participants without a cancer diagnosis and without suspicion of cancer: Age \>= 40 and =\< 75 * Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report * Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) * Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use * Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL * Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation * Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish \* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages * Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, hepatobiliary cancer, endometrial cancer or melanoma by clinical and/or radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw \* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma * Participants with a high suspicion of cancer: Central review of radiology reports and/or clinical documentation conducted by study chairs * Participants with a high suspicion of cancer: Age \>= 40 and =\< 75 * Participants with a high suspicion of cancer: No known current pregnancy by self-report * Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy. Non-melanoma skin cancers (such as basal or squamous cell) are allowed. * Participants with a high suspicion of cancer: Willingness to provide blood samples for research use * Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL * Participants with a high suspicion of cancer: No history or organ transplantation * Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeObservational
PhaseNot stated in the registry record
AllocationNot stated in the registry record
Intervention modelNot stated in the registry record
Primary purposeNot stated in the registry record
MaskingNot stated in the registry record
Enrolment2,900 participants sought

Sponsor and collaborators

  • Alliance for Clinical Trials in Oncology Sponsor
  • National Cancer Institute (NCI) Collaborators

Arms and interventions

  • Screening (questionnaire, biospecimen collection)

    Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.

Interventions

  • Procedure Biospecimen Collection

    Undergo collection of tissue and blood samples

  • Other Questionnaire Administration

    Complete questionnaire

Outcome measures

  1. Primary outcome

    Provision of blinded reference set of cancer versus non-cancer blood samples

    Diagnostic ability will be assessed across the entire cohort of 2000 subjects by estimating the sensitivity and specificity with 95% confidence intervals.

    Time frame Up to 1 year

  2. Secondary outcome

    Test performance at the time of initial cancer diagnosis by tumor type

    Diagnostic ability is assessed within each cancer type and within each cancer type and stage combination by estimating the sensitivity and specificity with 95% confidence intervals. The width of these confidence intervals will vary by sample size and the sensitivity and specificity rates.

    Time frame Up to 1 year

  3. Secondary outcome

    Test performance at the time of initial cancer diagnosis by clinical stage

    Diagnostic ability is assessed within each cancer stage and within each cancer type and stage combination by estimating the sensitivity and specificity with 95% confidence intervals. The width of these confidence intervals will vary by sample size and the sensitivity and specificity rates.

    Time frame Up to 1 year

Dates

Dates
Start dateAugust 18, 2022 (actual)
Primary completionJanuary 31, 2027 (estimated)
CompletionFebruary 28, 2027 (estimated)
First postedApril 19, 2022 (actual)
Last updatedNovember 4, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

619 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Providence Regional Cancer System-AberdeenAberdeenWashingtonRecruiting
Riverwood Healthcare CenterAitkinMinnesotaRecruiting
Cleveland Clinic Akron GeneralAkronOhioRecruiting
Summa Health System - Akron CampusAkronOhioRecruiting
Mayo Clinic Health System in Albert LeaAlbert LeaMinnesotaRecruiting
Lovelace Women's HospitalAlbuquerqueNew MexicoRecruiting
University of New Mexico Cancer CenterAlbuquerqueNew MexicoRecruiting
Presbyterian Kaseman HospitalAlbuquerqueNew MexicoRecruiting
Lovelace Medical Center-Saint Joseph SquareAlbuquerqueNew MexicoRecruiting
Lehigh Valley Hospital-Cedar CrestAllentownPennsylvaniaRecruiting
MyMichigan Medical Center GratiotAlmaMichiganRecruiting
MyMichigan Medical Center AlpenaAlpenaMichiganRecruiting
OSF Saint Anthony's Health CenterAltonIllinoisRecruiting
The Don and Sybil Harrington Cancer CenterAmarilloTexasRecruiting
McFarland Clinic - AmesAmesIowaRecruiting
Mary Greeley Medical CenterAmesIowaRecruiting
Community Hospital of AnacondaAnacondaMontanaRecruiting
Alaska Women's Cancer CareAnchorageAlaskaRecruiting
Anchorage Oncology CentreAnchorageAlaskaSuspended
Katmai Oncology GroupAnchorageAlaskaRecruiting
Providence Alaska Medical CenterAnchorageAlaskaRecruiting
Alaska Breast Care and Surgery LLCAnchorageAlaskaRecruiting
Anchorage Associates in Radiation MedicineAnchorageAlaskaRecruiting
Anchorage Radiation Therapy CenterAnchorageAlaskaSuspended
Alaska Oncology and Hematology LLCAnchorageAlaskaRecruiting
AnMed Health Cancer CenterAndersonSouth CarolinaRecruiting
UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkenyIowaRecruiting
Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn ArborMichiganRecruiting
Aspirus Cancer Care-Antigo-Volm Cancer CenterAntigoWisconsinRecruiting
ThedaCare Regional Medical Center - AppletonAppletonWisconsinRecruiting
ThedaCare Regional Cancer CenterAppletonWisconsinRecruiting
PCR OncologyArroyo GrandeCaliforniaRecruiting
Mission Hope Medical Oncology - Arroyo GrandeArroyo GrandeCaliforniaRecruiting
AdventHealth Infusion Center AshevilleAshevilleNorth CarolinaRecruiting
Northwest Wisconsin Cancer CenterAshlandWisconsinRecruiting
Duluth Clinic AshlandAshlandWisconsinRecruiting
Harold Alfond Center for Cancer CareAugustaMaineRecruiting
UCHealth University of Colorado HospitalAuroraColoradoRecruiting
Rush-Copley Medical CenterAuroraIllinoisSuspended
Rocky Mountain Cancer Centers-AuroraAuroraColoradoActive, not recruiting
The Medical Center of AuroraAuroraColoradoSuspended
Rocky Mountain Regional VA Medical CenterAuroraColoradoRecruiting
Advocate Outpatient Center - AuroraAuroraIllinoisRecruiting
Mount Sinai Comprehensive Cancer Center at AventuraAventuraFloridaRecruiting
Saint Alphonsus Cancer Care Center-Baker CityBaker CityOregonRecruiting
AIS Cancer Center at San Joaquin Community HospitalBakersfieldCaliforniaRecruiting
Mercy Oncology and Hematology - Clayton-ClarksonBallwinMissouriRecruiting
MedStar Franklin Square Medical Center/Weinberg Cancer InstituteBaltimoreMarylandRecruiting
Mercy Medical CenterBaltimoreMarylandRecruiting
Sinai Hospital of BaltimoreBaltimoreMarylandRecruiting

701 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 4, 2026

    Site added

    4 sites added (751 total)

    747751

  2. October 28, 2026

    Enrolment target changed

    Enrollment target revised up from 2000 to 2900

    20002900

  3. October 2, 2026

    Site added

    2 sites added (747 total)

    745747

  4. September 2, 2026

    Site added

    1 site added (745 total)

    744745

  5. August 5, 2026

    Site removed

    1 site removed (744 total)

    745744